PPAR-γ agonists and their effects on IGF-I receptor signaling: Implications for cancer

Area of Science:

• Oncology
• Endocrinology
• Pharmacology

Background:

• Dysregulation of the insulin-like growth factor (IGF) system is linked to various human cancers.
• Current IGF-targeting therapies face limitations due to insulin resistance and compensatory hyperinsulinemia, which can promote cancer growth.
• Novel therapeutic strategies are needed to overcome these limitations.

Purpose of the Study:

• To explore the potential of synthetic peroxisome proliferator-activated receptor-gamma (PPAR-γ) agonists, such as thiazolidinediones (TZDs), as anticancer agents.
• To investigate the mechanisms by which PPAR-γ agonists may exert anticancer effects, particularly their interaction with the IGF system.
• To evaluate the potential benefit of PPAR-γ agonists in managing cancers associated with hyperinsulinemia.

Main Methods:

• Review of existing literature on PPAR-γ agonists, IGF system signaling, and cancer development.
• Analysis of in vitro and in vivo studies demonstrating the anticancer effects of PPAR-γ agonists.
• Examination of the cross-talk between PPAR-γ and the IGF system.

Main Results:

• PPAR-γ agonists, including TZDs, exhibit pleiotropic anticancer effects beyond their insulin-sensitizing properties.
• These agents can downregulate the IGF system through cross-talk with its signaling components.
• The insulin-lowering action of PPAR-γ agonists may reduce cancer risk and progression in hyperinsulinemic individuals.

Conclusions:

• PPAR-γ agonists possess anticancer potential, particularly in tumors reliant on IGF signaling.
• Their ability to lower insulin levels makes them a promising therapeutic option for hyperinsulinemic patients with cancer.
• TZDs and other PPAR-γ agonists warrant further investigation for cancer treatment, especially in specific patient populations.